New study tracks hidden struggles of rare head and neck cancer survivors
NCT ID NCT05733091
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 300 people treated for sinonasal, nasopharyngeal, or skull base tumors to track their symptoms and functional changes over time. Participants will complete symptom questionnaires and undergo standard tests like hearing, eye, and speech exams. The goal is to learn how treatment affects daily life, so doctors can better support future patients.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could help doctors better understand and manage long-term symptoms and side effects for people treated for these rare head and neck tumors.
- What could go wrong
- This is an observational study, not testing a new treatment. It will not directly improve outcomes for participants, and results may take years to influence care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 300 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Dec 2018
- Expected to finish
-
Dec 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
M D Anderson Cancer Center
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion criteria: 1. Previously untreated patients with or suspected to have sinonasal malignancy or nasopharyngeal malignancy diagnosis based on either outside pathology report or MD Anderson pathology report. 2. Age ≥ 18 years 3. Plan to obtain the majority of treatment at MDACC including surgery and radiotherapy 4. Ability to understand and willingness to sign written informed consent Exclusion criteria: 1. History of the previous solid or liquid malignancies, apart from skin cancers treated with local therapy. 2. Existing neurocognitive impairment that is not the result of sinonasal and nasopharyngeal cancers or is treatment. 3. Previous treatment for sinonasal or nasopharyngeal carcinomas, apart from biopsy.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Nasopharyngeal malignancy are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Mapping the hidden toll of brain radiation on young minds
- AI analyzes 10,000 patient records to predict head and neck cancer recurrence
- New MRI technique could help surgeons avoid nerve damage
- New drug E7090 tested in patients with advanced solid tumors
- New MRI tracks Cancer's energy use to spot tumors